Replies to post #97202 on Biotech Values

[DewDiligence]

FDA approves ABT’s diagnostic for HIV antigen:

http://finance.yahoo.com/news/FDA-Approves-FirstofItsKind-prnews-3536864085.html?x=0&.v=1

In contrast to tests that detect only the antibodies to HIV, ABT’s test for HIV antigen can pick up infections that are still in the acute phase, leading to earlier commencement of antiviral therapy. ABT’s test also detects HIV antibodies.

[DewDiligence]

ABT ReadMeFirst

[Updates:
2Q10 results;
valuation relative to other Big Pharma;
monetizing Solvay’s vaccine business;
revisiting the ACCORD study;
nuke-sparing HIV program;
ABT licenses NBIX’s Elagolix for endometriosis;
Daclizumab starts phase-3 in MS;
FDA approves improved HIV diagnostic.]


Finances, outlook, and valuation
#msg-51791410 Which are the most attractive Big Pharma? (Jun 2010)
#msg-53395171 2Q10 financial results
#msg-46843833 ABT hikes dividend for 38th consecutive year!
#msg-32844386 New $5B buyback authorization
#msg-51800455 Monetizing Solvay’s vaccine business
#msg-47606240 2010 guidance unchanged by Facet buyout
#msg-35632310 Feb 2009 feature in Barron’s


Acquisitions (in reverse chronological order)
#msg-50436738 Piramal
#msg-50473238 India’s fake drugs are a real problem
#msg-50438863 Further rationale for Piramal deal
#msg-50022514 Zydus Cadila
#msg-47606240 Facet Biotech
#msg-43510907 Anti-NGF mAb for pain
#msg-41922225 Solvay Pharmaceuticals
#msg-41374735 Evalve
#msg-41143330 Visiogen
#msg-34762429 Advanced Medical Optics (AGN spin-off)
#msg-34244326 Ibis Biosciences (former ISIS subsidiary)
#msg-14553895 Kos Pharmaceuticals
#msg-10772808 Guidant vascular business (PR)
#msg-9314269 Guidant vascular business (commentary)
#msg-34774636 Jan 2009 feature in WSJ


Cholesterol franchise (including JV with AZN)
#msg-43586320 Niaspan bests Zetia in ARBITER 6–HALT study
#msg-38554134 Niaspan lowers level of lipoprotein
#msg-51992958 Revisiting the ACCORD study
#msg-47808752 TriCor fails to impress in ACCORD study (PR)
#msg-47808450 TriCor fails to impress in ACCORD study (Reuters)
#msg-48400231 FDA issues CRL for Certriad
#msg-33263372 Crestor JUPITER data could be game-changer
#msg-33503193 TriLipix 1-Year combo data
#msg-34203456 FDA approves TriLipix
#msg-26869744 FDA approves Simcor
#msg-28510348 Heart disease: Not about cholesterol?
#msg-43674310 What’s up with MRK’s Cordaptive?


Drug business (general)
#msg-53395171 Humira continues on monster pace
#msg-51343858 ABT licenses NBIX’s Elagolix for endometriosis
#msg-50509176 Daclizumab starts phase-3 in MS
#msg-39417561 Size and segments of US market for RA
#msg-26156472 FDA approves Humira for plaque psoriasis
#msg-52406597 Nuke-sparing HIV program (Kaletra+Isentress)
#msg-50894737 Oncology pipeline
#msg-47060142 Multi-pronged program in HCV
#msg-29106939 ADHD program


Xience
#msg-39762286 DES US/global market shares (2Q09)
#msg-32873087 Xience ramp exceeds forecasts (1)
#msg-32217694 Xience ramp exceeds forecasts (2)
#msg-42404723 Xience bests Taxus in ‘real world’ SPIRIT IV
#msg-41731638 Xience blows away Taxus at three years in SPIRIT III
#msg-41855797 Xience makes Taxus Liberté irrelevant (1)
#msg-45284964 Xience makes Taxus Liberté irrelevant (2)
#msg-46547744 Taxus is fading fast (4Q09 numbers)
#msg-38097301 Xience shines in hard-to-treat subgroups
#msg-30452522 FDA approves Xience
#msg-38985789 EU approves Xience Prime
#msg-45262545 Xience approved in Japan
#msg-41529862 Xience approved in China


Bio-resorbable stent
#msg-50956393 Six-month data from second cohort (n=101)
#msg-43664045 Three-year data from first cohort (n=30)
#msg-36292361 WSJ blurb (Mar 2009)
#msg-32869939 Business Week feature (Oct 2008)


Corporate, legal, and miscellaneous
#msg-31637906 ABT cuts costs with 1,000-job reduction
#msg-44080721 ABT, Teva settle TriCor patent case
#msg-39903651 ABT wins $400M patent settlement from MDT
#msg-37562781 ABT sues JNJ on Simponi patent
#msg-39161889 Jury hits ABT with $1.7B award in Humira suit
#msg-43335667 Judge refuses to reduce Humira damages
#msg-31102936 Musings on Norvir (ritonavir) lawsuit
#msg-51547194 FDA approves improved HIV diagnostic
#msg-40949294 Cancer-biomarker collaboration with PFE
#msg-39511634 Cancer-biomarker collaboration with GSK
#msg-45878816 Litigation vis-à-vis blood glucose monitoring